Full Text View
Tabular View
No Study Results Posted
Related Studies
Treatment of High Blood Pressure Using Olmesartan With Hydrochlorothiazide Compared to an ACE Inhibitor With a Calcium Channel Blocker
This study has been completed.
First Received: September 9, 2005   Last Updated: March 27, 2007   History of Changes
Sponsor: Daiichi Sankyo Inc.
Information provided by: Daiichi Sankyo Inc.
ClinicalTrials.gov Identifier: NCT00185120
  Purpose

A comparison of 2 different combinations of high blood pressure medications to treat hypertension


Condition Intervention Phase
Hypertension
 Drug: Olmesartan medoxomil
Drug: Hydroclorothiazide
Drug: Benazepril
Drug: Amlodipine
 Phase IV

Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study
Official Title: A Study on the Efficacy and Safety of Olmesartan Medoxomil and Its Combination With Hydrochlorothiazide Compared With an ACE Inhibitor and Its Combination With a Calcium Channel Blocker in Patients With Stage 2 Hypertension

Resource links provided by NLM:

MedlinePlus related topics: Calcium High Blood Pressure
Drug Information available for: Hydrochlorothiazide Benazepril hydrochloride Benazepril Amlodipine Amlodipine besylate Olmesartan Olmesartan medoxomil Lotrel Calcium gluconate
U.S. FDA Resources

Further study details as provided by Daiichi Sankyo Inc.:

Primary Outcome Measures:
  • Change in systolic blood pressure from the start of the study

Secondary Outcome Measures:
  • Change in diastolic blood pressure from the start of the study
  • Percent of patients who achieve target blood pressure goals

Estimated Enrollment: 152
Study Start Date: September 2005
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Greater than 18 years of age
  • Patients with high blood pressure

Exclusion Criteria:

  • Hypertensive encephalopathy, stroke or transient ischemic attack within the past 6 months
  • History of myocardial infarction, percutaneous transluminal coronary revascularization, coronary artery bypass graft, and/or unstable angina pectoris within the past 6 months
  • Type 1 diabetes mellitus
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00185120

Locations
United States, Alabama
Mobile, Alabama, United States, 36693
United States, California
Memorial Research Medical Center
Long Beach, California, United States, 90806
National Research Institute
Los Angeles, California, United States, 90057
Orange County Research Center
Tustin, California, United States, 92780
Westlake Medical Center
Westlake Village, California, United States, 91361
Apex Research Institute
Santa Ana, California, United States, 92705
Clinical Trials Research
Roseville, California, United States, 95661
United States, Florida
SFBC International
Miami, Florida, United States, 33142
The Greater Fort Lauderdale Heart Group Research
Fort lauderdale, Florida, United States, 33308
CLIRECO, Inc.
Tamarac, Florida, United States, 33321
Clinical Research of South Florida
coral gables, Florida, United States, 33134
United States, Indiana
Midwest Institute for Clinical Research
Indianapolis, Indiana, United States, 46260
United States, Kansas
Heartland Research Associates
Wichita, Kansas, United States, 67207
United States, Maine
Androscoggin Cardiology Research
Auburn, Maine, United States, 04210
United States, North Carolina
Internal Medicine Associates of Charlotte
Charlotte, North Carolina, United States, 28211
Piedmont Medical Research Associates
Winston-salem, North Carolina, United States, 27103
United States, Ohio
The Lindner Clinical Trial Center
Cincinnati, Ohio, United States, 45319
United States, Rhode Island
Omega Medical Research
Warwick, Rhode Island, United States, 02886
United States, Tennessee
Volunteer Research Group, University of Tennessee Med. Ctr.
Knoxville,, Tennessee, United States, 37920
United States, Texas
Punzi Medical Center
Carrollton, Texas, United States, 75006
Sponsors and Collaborators
Daiichi Sankyo Inc.
  More Information

No publications provided

Study ID Numbers: 866-447
Study First Received: September 9, 2005
Last Updated: March 27, 2007
ClinicalTrials.gov Identifier: NCT00185120     History of Changes
Health Authority: United States: Food and Drug Administration

Keywords provided by Daiichi Sankyo Inc.:
Hypertension
angiotensin receptor blocker
calcium channel blocker
angiotensin converting enzyme inhibitor hydroclorothiazide

Additional relevant MeSH terms:
Vasodilator Agents
Molecular Mechanisms of Pharmacological Action
Sodium Chloride Symporter Inhibitors
Physiological Effects of Drugs
Diuretics
Vascular Diseases
Calcium Channel Blockers
Olmesartan medoxomil
Enzyme Inhibitors
Cardiovascular Agents
Antihypertensive Agents
Hydrochlorothiazide
 Pharmacologic Actions
Amlodipine
Protease Inhibitors
Angiotensin II Type 1 Receptor Blockers
Membrane Transport Modulators
Natriuretic Agents
Therapeutic Uses
Benazepril
Angiotensin-Converting Enzyme Inhibitors
Cardiovascular Diseases
Hypertension

ClinicalTrials.gov processed this record on February 08, 2010



Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services